Heterocyclic inhibitors of glycogen synthase kinase GSK-3
AssigneeConsejo Superior de Investigaciones Cientificas
InventorsAna Martinez Gil, Ana Castro Morera, Maria Concepcion Martin Perez, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Francisco Jose Moreno Munoz, Francisco Wandosell Jurado
Life of this patent
Estimating the term…
Abstract
Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.
Claims25
Compounds of general formula (I):
- wherein:
- A is —NR1—;
- E is —NR1—;
- G is —S—;
- each R1 is independently selected from haloalkyl, —OR3, —C(O)R3, —C(O)OR3, —(Z)n—C(O)OR3 and —S(O)t—;
- Z is independently selected from —C(R3)(R4)—, —C(O)—, —O—, —C(═NR3)—, —S(O)t— and N(R3)—;
- n is zero, one, or two;
- t is zero, one, or two;
- R3 and R4 are independently selected from hydrogen, alkyl, and aryl and
- X and Y are independently selected from ═O and ═S.
A pharmaceutical composition comprising a compound having formula (I) as an active ingredient and a pharmaceutically acceptable carrier or diluent:
- wherein:
- A is —NR1—;
- E is —NR1—;
- G is —S—;
- - - - is absent;
- each R1 is independently selected from hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, —(Z)n-aryl, —OR3, —C(O)R3, —C(O)OR3, —(Z)n—C(O)OR3, and —S(O)t—;
- Z is independently selected from —C(R3)(R4)—, —C(O)—, —O—, —C(═NR3)—, —S(O)t— and N(R3)—;
- n is zero, one, or two;
- t is zero, one, or two;
- R3 and R4 are independently selected from hydrogen, alkyl, and aryl;
- and
- X and Y are independently selected from ═O and ═S.
Dependencies are inferred from the claim text.